Envista (NYSE:NVST) Stock Rating Upgraded by Leerink Partners

Envista (NYSE:NVST) was upgraded by research analysts at Leerink Partners from a “hold” rating to an “outperform” rating in a research report issued on Friday, Marketbeat Ratings reports. The brokerage presently has a $35.00 target price on the stock. Leerink Partners’ price target indicates a potential upside of 19.99% from the stock’s current price.

NVST has been the topic of a number of other research reports. JPMorgan Chase & Co. boosted their price objective on Envista from $22.00 to $26.00 and gave the stock a “neutral” rating in a research note on Friday. Piper Sandler reiterated a “neutral” rating and set a $25.00 target price (up from $21.00) on shares of Envista in a report on Friday. Evercore reissued an “outperform” rating and set a $32.00 price target on shares of Envista in a research report on Friday. Weiss Ratings restated a “sell (d)” rating on shares of Envista in a report on Monday, December 29th. Finally, Wall Street Zen upgraded shares of Envista from a “buy” rating to a “strong-buy” rating in a research note on Monday, January 26th. Eight equities research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $26.50.

Envista Price Performance

NVST opened at $29.17 on Friday. Envista has a 52-week low of $14.22 and a 52-week high of $29.28. The company has a 50 day moving average of $22.80 and a two-hundred day moving average of $21.24. The company has a market cap of $4.80 billion, a P/E ratio of 104.18, a P/E/G ratio of 1.29 and a beta of 1.01. The company has a quick ratio of 2.02, a current ratio of 2.37 and a debt-to-equity ratio of 0.47.

Envista (NYSE:NVST) last issued its earnings results on Thursday, February 5th. The company reported $0.38 EPS for the quarter, beating analysts’ consensus estimates of $0.32 by $0.06. Envista had a net margin of 1.73% and a return on equity of 6.55%. The business had revenue of $750.60 million for the quarter, compared to the consensus estimate of $680.26 million. During the same quarter last year, the firm posted $0.24 EPS. The business’s revenue for the quarter was up 15.0% compared to the same quarter last year. Envista has set its FY 2026 guidance at 1.350-1.450 EPS. On average, analysts expect that Envista will post 1 earnings per share for the current year.

Institutional Trading of Envista

A number of hedge funds and other institutional investors have recently made changes to their positions in NVST. Farther Finance Advisors LLC grew its holdings in Envista by 317.6% during the 3rd quarter. Farther Finance Advisors LLC now owns 1,349 shares of the company’s stock worth $27,000 after acquiring an additional 1,026 shares in the last quarter. Caitong International Asset Management Co. Ltd raised its stake in shares of Envista by 16,711.1% in the 3rd quarter. Caitong International Asset Management Co. Ltd now owns 1,513 shares of the company’s stock valued at $31,000 after purchasing an additional 1,504 shares in the last quarter. Allworth Financial LP lifted its position in shares of Envista by 75.4% during the fourth quarter. Allworth Financial LP now owns 1,805 shares of the company’s stock worth $39,000 after purchasing an additional 776 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in shares of Envista by 73.1% during the second quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 2,248 shares of the company’s stock worth $44,000 after purchasing an additional 949 shares during the last quarter. Finally, IFP Advisors Inc grew its stake in Envista by 102.9% in the fourth quarter. IFP Advisors Inc now owns 2,112 shares of the company’s stock worth $46,000 after purchasing an additional 1,071 shares in the last quarter.

Envista News Summary

Here are the key news stories impacting Envista this week:

• Positive Sentiment: Q4 results beat expectations — Envista reported $0.38 EPS vs. $0.32 consensus and revenue of $750.6M versus ~ $680M est., with revenue up ~15% year-over-year. Strong results are the primary driver of the move higher. Envista Reports Fourth Quarter 2025 Results
• Positive Sentiment: Management raised FY‑2026 EPS guidance to $1.35–$1.45 vs. consensus ~ $1.27 — the stronger outlook (and beat + guidance combo) is supportive of the rally and suggests better-than-expected near-term growth. Press Release / Slide Deck
• Neutral Sentiment: Earnings materials and call transcripts are available for deeper read — the conference call transcript and slide deck provide management commentary on drivers (product mix, geographic trends, margins) that investors should review to judge sustainability. Earnings Call Transcript Earnings Presentation
• Neutral Sentiment: Wall‑street writeups and snapshots (Zacks, Yahoo, Investing) highlight the beat and value/Growth characteristics — useful for screening but not new catalysts by themselves. Zacks Q4 Metrics
• Negative Sentiment: Analyst targets still imply downside — JPMorgan and Wells Fargo both raised targets to $26 but kept neutral/equal‑weight ratings; those $26 targets sit below the current market level, which could cap upside or prompt caution once headline momentum fades. Benzinga – JPMorgan Benzinga – Wells Fargo

About Envista

Envista Holdings Corporation is a global dental products company that develops, manufactures and markets a broad portfolio of dental consumables, equipment and technology solutions. Headquartered in Brea, California, Envista serves dental practitioners, specialists and laboratories in more than 150 countries. The company’s offerings span implant, orthodontic, endodontic and restorative product lines as well as digital imaging systems and practice management software.

Envista’s product brands include Nobel Biocare for dental implants and restorative solutions, Ormco for orthodontic appliances and treatment systems, Kerr for restorative and endodontic materials, KaVo for dental imaging and handpieces, and Vista for surgical drills and instruments.